Uveitis Treatment - Global Market Trajectory & Analytics

Global Uveitis Treatment Market to Reach $875.5 Million by 2027

Amid the COVID-19 crisis, the global market for Uveitis Treatment estimated at US$640.1 Million in the year 2020, is projected to reach a revised size of US$875.5 Million by 2027, growing at a CAGR of 4.6% over the period 2020-2027.



The U.S. Market is Estimated at $188.5 Million, While China is Forecast to Grow at 4.3% CAGR

The Uveitis Treatment market in the U.S. is estimated at US$188.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$154.9 Million by the year 2027 trailing a CAGR of 4.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Select Competitors (Total 42 Featured):

• AbbVie, Inc.
• Alcon, a Novartis Company
• Allergan PLC
• Bausch & Lomb, Inc.
• Enzo Biochem, Inc.
• Hanbell Precise Machinery Co. Ltd.
• Psivida Corporation
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• TopiVert Ltd.
• XOMA Corporation